Melanoma is the most dangerous form of common skin cancer. Although it accounts for only a small fraction of skin cancer diagnoses, it is responsible for a disproportionate share of skin cancer deaths. Globally, about 331,722 people are diagnosed with melanoma each year and roughly 58,667 die from it. How dangerous it is for any individual depends almost entirely on how early it’s caught: the five-year survival rate for localized melanoma is 97.6%, but once it spreads to distant organs, that number drops to 16.2%.
Why Melanoma Is More Dangerous Than Other Skin Cancers
Basal cell and squamous cell carcinomas, the two most common skin cancers, grow slowly and rarely spread beyond the skin. Melanoma behaves differently. It arises from melanocytes, the pigment-producing cells in your skin, and it has an unusual ability to invade the lymphatic system and bloodstream early in its development.
Research from the National Cancer Institute has revealed a key reason melanoma spreads so effectively. When melanoma cells travel through the lymphatic system before entering the bloodstream, they pick up high levels of a fatty acid called oleic acid. This oleic acid gets incorporated into the outer membranes of the cancer cells, shielding them from a type of cell death called ferroptosis, which normally kills cancer cells exposed to oxidative stress in the blood. As one researcher described it, the melanoma cells “load up on oleic acid in the lymph, and then once they go into the blood, they’re bulletproof.” This is why melanoma can establish new tumors in distant organs like the lungs, liver, and brain far more readily than other skin cancers.
How Stage Determines Survival
The single biggest factor in how dangerous a melanoma is to you is how far it has progressed at diagnosis. Melanoma is staged from 0 (in situ, meaning confined to the top layer of skin) through IV (spread to distant organs).
- Localized (Stages I and II): The cancer is confined to the skin. Five-year survival is 97.6%.
- Regional (Stage III): The cancer has reached nearby lymph nodes or surrounding tissue. Five-year survival drops to 60.3%.
- Distant (Stage IV): The cancer has spread to distant organs. Five-year survival is 16.2%.
These numbers make the contrast stark. A thin, early melanoma is one of the most curable cancers. A late-stage melanoma is one of the most lethal.
Tumor Thickness and What It Means
Within each stage, the physical depth of the tumor in the skin, measured in millimeters, is a powerful predictor of outcome. This measurement is called the Breslow depth. Tumors are grouped into four categories: 0.75 mm or less, 0.76 to 1.5 mm, 1.51 to 4 mm, and greater than 4 mm.
Data on acral lentiginous melanoma (a subtype discussed below) illustrates how thickness affects survival across all melanoma types. Tumors thinner than 1 mm had a five-year survival of 95.5%. Between 2 and 4 mm, that dropped to 69.6%. Tumors thicker than 4 mm had a five-year survival of just 51.4%. Each additional millimeter of depth represents more opportunity for cancer cells to reach blood vessels and lymphatic channels beneath the skin.
When a primary melanoma reaches at least 0.8 mm in thickness, doctors typically recommend a sentinel lymph node biopsy to check whether cancer cells have already begun migrating.
How Quickly It Can Become Dangerous
Treatment delays, even short ones, measurably worsen outcomes. A population-based study found that for Stage I melanoma, delays of just one month in surgical treatment were associated with worse overall mortality. Delays of three to five months were linked to worse melanoma-specific mortality. For Stage II disease, delays of three to five months worsened overall mortality, and delays beyond six months worsened melanoma-specific mortality.
This is significant because Stage I melanoma is supposed to be the “safe” stage. Even at this early point, waiting too long to remove the tumor can shift the odds against you.
Recurrence Risk After Treatment
Even after successful surgical removal, melanoma can return. The risk of recurrence varies dramatically by stage. For Stage IA melanoma (the thinnest, most superficial tumors), the five-year recurrence rate is only 1.6%. But for Stages IIB through IIC and Stages IIIB through IV, more than half of all recurrences happen within the first two years.
This timeline shapes how long you’ll need follow-up monitoring. For Stage IA and IB melanomas, recurrence risk typically falls below 5% within four to five years. For Stage III disease, that threshold extends well beyond five years, meaning longer surveillance with skin checks and imaging.
Some Types Are More Dangerous Than Others
Not all melanomas carry the same risk. The most common subtype, superficial spreading melanoma, tends to grow outward across the skin surface before invading deeper layers, giving you more time to notice it. Nodular melanoma, by contrast, grows downward from the start and is often thicker at diagnosis.
Acral lentiginous melanoma (ALM) develops on the palms, soles, or under the nails. It accounts for only 2% to 3% of all melanomas but carries a worse prognosis: five-year survival of 80.3% compared to 91.3% for melanoma overall. The reason is largely about detection. Only 41.3% of ALMs are caught when they’re still thinner than 1 mm, compared to 70% of melanomas in general. Because these tumors appear in locations people don’t regularly examine, and because they’re more common in people with darker skin who may not think of themselves as at risk for skin cancer, they’re caught later and at greater thickness. Among Asian and Pacific Islander patients, 22% of ALMs were thicker than 4 mm at diagnosis.
How Treatment Has Changed the Outlook
For advanced melanoma, the landscape has shifted substantially. Before the development of modern immunotherapy, Stage IV melanoma was almost universally fatal within a year or two. Newer treatments that help the immune system recognize and attack melanoma cells have extended median overall survival for metastatic disease to about 24.3 months, compared to 15.6 months with traditional chemotherapy. The time before the cancer progresses also improved, from 7.8 months with chemotherapy to 12.4 months with immunotherapy.
These numbers represent medians, meaning half of patients do better and half do worse. Some patients with advanced melanoma now survive many years on immunotherapy, a result that was essentially unheard of a decade ago. Still, Stage IV melanoma remains a serious diagnosis, and the survival improvements underscore why catching it early matters so much more than treating it late.
What to Watch For on Your Skin
The standard checklist for suspicious moles uses the ABCDE criteria: Asymmetry (one half doesn’t match the other), Border irregularity (ragged or blurred edges), Color variation (multiple shades of brown, black, red, or blue within one spot), Diameter greater than 6 mm (about the size of a pencil eraser), and Evolution (any change in size, shape, or color over time).
Later warning signs include itching, ulceration, or bleeding from a mole. On the palms, soles, and nails, look for a dark streak or a spot that’s growing or changing color. Risk factors include a history of sunburns, fair skin, a large number of moles, family history of melanoma, and a weakened immune system.